Report on a Phase III insomnia trial clearing an interim review and the planned recruitment, regulatory engagement, and commercialization steps.
Key Takeaways
- Independent DMB unanimously recommended continuing the trial to 519 participants
- Participants are randomized to nightly 75 mg, 150 mg, or placebo for eight weeks
- Australian commercial rights were licensed to Sandoz for US$3 million upfront